Skip to main content
. 2021 Apr;11(4):a034975. doi: 10.1101/cshperspect.a034975

Table 1.

The European LeukemiaNET (ELN) 2017 risk stratification of acute myeloid leukemia (AML)

Risk category Genetic abnormality
Favorable

  • t(8;21)(q22;q22.1); RUNX1-RUNX1T1

  • inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

  • Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow = allelic ratio < 0.5

  • Biallelic mutated CEBPA
Intermediate

  • Mutated NPM1 and FLT3-ITDhigh = allelic ratio > 0.5

  • Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without adverse-risk genetic lesions)

  • t(9;11)(p21.3;q23.3); MLLT3-KMT2A

  • Cytogenetic abnormalities not classified as favorable or adverse
Adverse

  • t(6;9)(p23;q34.1); DEK-NUP214

  • t(v;11q23.3); KMT2A rearranged

  • t(9;22)(q34.1;q11.2); BCR-ABL1

  • inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)

  • −5 or del(5q); −7; −17/abn(17p)

  • Complex karyotype, monosomal karyotype

  • Wild-type NPM1 and FLT3-ITDhigh

  • Mutated RUNX1

  • Mutated ASXL1

  • Mutated TP53

Data reprinted from Döhner et al. (2017), with permission from The American Society of Hematology, © 2017.